MAPT and Alzheimer disease: Enzyme-linked immunosorbent assay (ELISA)-based analyses of specific AD-associated proteins, namely cerebrospinal fluid (CSF) Aβ42 and tau protein, have been the first routinely used approaches in fluid biomarker studies in dementia as well as in clinical daily work [1].